ArticleJAAD case reports2018
Cutaneous CD56
Article in JAAD case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Drug- and Vaccine-Induced Cutaneous T-Cell Lymphoma: A Systematic Review of the Literature.Journal of skin cancer · 2025Review
- Abrupt progression from patch- to tumor-stage mycosis fungoides following pembrolizumab treatment.JAAD case reports · 2024Article
- Sézary syndrome associated vitiligo-like leukoderma in type V skin: Report of a case and review of the literature.JAAD case reports · 2024Article
- Cutaneous T cell lymphoma.Nature reviews. Disease primers · 2021Review
- Newly diagnosed follicular lymphoma during pembrolizumab treatment for lung cancer.International journal of hematology · 2021Article
- CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.Thoracic cancer · 2021Article
- Updating targets for natural killer/T-cell lymphoma immunotherapy.Cancer biology & medicine · 2021Review
- Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.Frontiers in immunology · 2020Article
- Pembrolizumab-associated tumor development in a patient with Sézary syndrome.JAAD case reports · 2020Article
- Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.Oncoimmunology · 2020Article
- Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.Journal of immunology research · 2020Review
- Immunomodulation in Cutaneous T Cell Lymphoma.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.